Horizon Performance TMS (transcranial magnetic stimulation) therapy system receives 510(K) approval from the FDA and CE Mark for use to treat depression.- Magstim
Magstim, the pioneer of a ground-breaking, non-invasive treatment for depression, has announced that the FDA has issued 510(k) clearance of the Horizon Performance TMS (Transcranial Magnetic Stimulation therapy) system and is making it immediately available for sale in the US.
Transcranial Magnetic Stimulation (rTMS), an innovative and proven therapy which uses a series of repetitive, brief and highly focused magnetic pulses to stimulate the brain. The Horizon Performance is a best in class therapy solution for clinicians, allowing greater flexibility for patient treatment with few known side effects. In depressed patients, electrical activity in certain areas of the brain is reduced. Magstim TMS therapy from Horizon Performance uses a focused electromagnetic coil to rapidly pulse a magnetic field to the targeted area of the brain. This induces a small electrical current which stimulates the targeted brain cells into activity, increasing brain activity back to a normal level.
Comment: The Horizon Performance TMS system received CE Mark recommendation on 13 July 2018.
Related news and insights
Medtronic announced the United States launch of the Penditure left atrial appendage (LAA) exclusion system, an implantable clip preloaded on a single-use delivery system for LAA management during concomitant cardiac surgery procedures
GSK plc announced positive headline results from a planned interim efficacy analysis of the DREAMM-7 head-to-head phase III trial evaluating belantamab mafodotin as a second-line treatment for relapsed or refractory multiple myeloma